CN106421137A - Compound preparation for treating chronic pharyngitis - Google Patents
Compound preparation for treating chronic pharyngitis Download PDFInfo
- Publication number
- CN106421137A CN106421137A CN201611024270.1A CN201611024270A CN106421137A CN 106421137 A CN106421137 A CN 106421137A CN 201611024270 A CN201611024270 A CN 201611024270A CN 106421137 A CN106421137 A CN 106421137A
- Authority
- CN
- China
- Prior art keywords
- preparation
- compound
- chronic pharyngitis
- medicine
- compound preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a compound preparation for treating chronic pharyngitis, as a western medicine compound preparation, prepared from, by weight, 0.05-1.2% of verapamil, 0.01-1.0% of tea polyphenols, 0.03-1.5% of allicin, 0.005-0.018% of glucocorticoid pharmaceutical, 0.001-0.005% of vitamin B, and 0.01-0.5% of taurine. The compound preparation for treating chronic pharyngitis according to the invention has the advantages of zero toxic and side effects, avoidance of complications after long-term administration, short treatment course, and good treatment effect; the compound preparation has good taste, a production method is simple, and production cost is low; the compound preparation for treating chronic pharyngitis has good anti- tussive, anti-inflammatory and antibacterial effects.
Description
Technical field
The present invention relates to technical field of western medicines, specifically a kind of compound preparation treating chronic pharyngitis.
Background technology
Chronic pharyngitis is pharynx mucous membrane, under mucous membrane and adenoid chronic inflammation.Diffusivity pharyngeal inflammation is often upper breathing
A part for road chronic inflammation；Limitation pharyngeal inflammation mostly then is pharynx lymphoid tissue inflammation.This disease is common in clinic, the course of disease
Long, the easy recurrent exerbation of symptom.From pathology, chronic pharyngitis can be divided into following 5 classes：First, chronic simple pharyngitis；2nd, slow
Property hyperplastic pharyngitis；3rd, atrophic and pharyngitis sicca；4th, chronic anaphylaxis pharyngitis；5th, chronic reflux pharyngitis.
Chronic pharyngitis is more common in adult, and children also may occur in which.Constitutional symptom is all inconspicuous, based on local symptom.Respectively
Type chronic pharyngitis symptom is substantially similar and varied, such as pharyngeal sense of discomfort, foreign body sensation, pharyngeal secretion be difficult to bring up, pharyngeal
Gargalesthesia, burn feeling, dry sensation or excitement, also can have hypodynia sense.Because pharynx rear wall is generally because pharyngeal chronic inflammation causes relatively to stick
Thick secretion adhesion, and because nose, nasal sinus, nasopharynx pathological changes cause night mouth breathing, excitant occurs when Chang Chen rises
Cough and nausea.Because foreign body in pharynx sense can behave as frequently swallowing.Pharyngeal secretion few and be difficult expectoration person often show as practise
The dry cough of inertia and expectoration action of clearing one's throat, if firmly cough or clear one's throat to cause pharyngeal mucosa hemorrhage, cause in secretion
Band blood.
The treatment method of existing chronic pharyngitis：Compound borax, furacilin solution are commonly used for chronic simple pharyngitis
Deng containing gargling, keep oral cavity, pharyngeal cleaning；Or the lozenge of the pharyngeal chronic inflammation for the treatment of such as buccal iodine lozenge, Mint throat lozenge；Chinese medicine
Preparation is as also having certain curative effect to chronic pharyngitis；The weak albumen of the available glycerinum iodi compositum in local, 5% silver nitrate solution or 10%
Silver-colored solution smear pharyngeal, have convergence and antiinflammation；Ultrasonic atomizatio can alleviate the symptom of chronic pharyngitis.At present for chronic fertilizer
The treatment of thickness pharyngitis is more difficult, general reference chronic simple pharyngitis treatment.Atrophic and pharyngitis sicca are typically located
Manage same chronic simple pharyngitis, but unavailable inustion, can take or pharyngeal partial smearing low dose idodine is to promote on mucous membrane
Skin secretion increases；Ultrasonic atomization therapy also can mitigate symptom is dried；Take vitamin A, B2, C, E, pharyngeal mucosal epithelium can be promoted
Tissue increases；Patient for pharyngitis sicca is it is considered to should be prudent during row tonsillectomy, in order to avoid postoperative aggravation.Right
Avoid contact with various possible anaphylactogens, application Loratadine or mast cell stabilizers, office in chronic allergia pharyngitis
Portion or the glucocorticoid of whole body application in a short time and immunomodulator etc..Edible promotion hydrochloric acid in gastric juice is avoided for chronic reflux pharyngitis
The food of secretion, such as chocolate, food of pungent stimulation etc. is reducing bottleneck throat reflux situation to reduce the thorn to pharyngeal mucous membrane
Swash；Sleep front 3-4 hour and control feed inflow；Available acid inhibitor and stomach lining on the basis of the general process of chronic pharyngitis
Protective agent partner treatment, active treatment gastric lesions simultaneously.
Existing treatment of chronic pharyngitis method is a lot, but effect is very different, and a lot of Western medicine has very big pair
, easily complication in effect after long-term taking；And not only treatment cycle is long to use Chinese medicine, therapeutic effect is poor, and drug port
Sense is poor.Accordingly, it would be desirable to a kind of Small side effects, the complication that will not cause, low production cost, eutherapeutic for treating chronic pharyngitis
Compound preparation.
Content of the invention
It is an object of the invention to provide a kind of compound preparation treating chronic pharyngitis, to solve to carry in above-mentioned background technology
The problem going out.
For achieving the above object, the present invention provides following technical scheme：
A kind of compound preparation treating chronic pharyngitis, described compound Western medicine preparation includes effective group of following parts by weight
Point：Verapamil 0.05-1.2%, Tea Polyphenols 0.01-1.0%, allicin 0.03-1.5%, glucocorticoid medicine
0.005-0.018%, vitamin B2 0.001-0.005%, taurine 0.01-0.5%.
As the further scheme of the present invention：Described glucocorticoid medicine is dexamethasone, Triamcinolone acetonide, cloth ground how
One of moral, hydrocortisone.
As the present invention further scheme：Described compound Western medicine preparation includes the active principle of following parts by weight：
Verapamil 0.06-0.35%, Tea Polyphenols 0.05-0.65%, allicin 0.05-0.65%, glucocorticoid medicine
0.012-0.017%, vitamin B2 0.002-0.004%, taurine 0.12-0.25%.
As the present invention further scheme：Described compound Western medicine preparation includes the active principle of following parts by weight：
Verapamil 0.12%, Tea Polyphenols 0.15%, allicin 0.55%, glucocorticoid medicine 0.015%, vitamin
B20.003%, taurine 0.15%.
As the present invention further scheme：Described compound Western medicine preparation is tablet, granule, oral administration solution, spraying
Agent or nasal drop.
As the present invention further scheme：Described compound Western medicine preparation is buccal tablet or oral administration solution.
As the present invention further scheme：The preparation method of described buccal tablet is：(1) weigh Verapamil 0.5-
12g, Tea Polyphenols 0.1-10g, allicin 0.3-15g, glucocorticoid medicine 0.05-0.18g, vitamin B2 0.01-
0.05g, taurine 0.1-5g, are mixed with 50g malt saccharin respectively, sieve, add 250-400g Icing Sugar, sieve, mixed
Close powder；(2) menthol containing sheet weight 0.6-1% is dissolved in 175-200mL absolute ethyl alcohol, adds in mixed-powder, mixing
Uniformly, dry；(3) with the 65-75% syrup of 120-150mL or 1-3%HPMC solution 110-115mL as adhesive, softwood processed
And granulation of sieving；(4) whole grain compressing tablet, prepared compound buccal tablet.
As the present invention further scheme：The preparation method of described oral administration solution is：(1) weigh Verapamil 0.5-
12g, Tea Polyphenols 0.1-10g, allicin 0.3-15g, glucocorticoid medicine 0.05-0.18g, vitamin B2 0.01-
0.05g, taurine 0.1-5g, standby；(2) by Verapamil 0.5-12g, vitamin B2 0.01-0.05g and Tea Polyphenols 0.1-
10g 150-250mL distills water dissolves, adds 55-60g 350-400mL to distill water-soluble Tween 80, stirring and dissolving is mixed
Even；(3) it is separately added into aqueous solution 55-80mL, the dissolving 0.3-15g garlic of dissolving 0.05-0.18g glucocorticoid medicine again
Element and 0.1-5g taurine aqueous solution 55-80mL and be dissolved in 250-300mL temperature be 55-105 DEG C of hot water in 8-10g peppermint
Brain, uniformly obtains final product oral administration solution using ultrasonic mixing.
Compared with prior art, the invention has the beneficial effects as follows：
The compound preparation of the treatment chronic pharyngitis of the present invention have have no toxic side effect, be not in concurrent after long-term taking
Disease, the advantage that treatment cycle is short, therapeutic effect is good；And medicine is in good taste, production method is simple, low production cost；By reality
The compound preparation demonstrating this treatment chronic pharyngitis has good cough-relieving, anti-inflammatory, bacteriostasis, has preferable promotion price
Value.
Specific embodiment
With reference to specific embodiment, the technical scheme of this patent is described in more detail.
Embodiment 1
A kind of compound preparation treating chronic pharyngitis, described compound Western medicine preparation includes effective group of following parts by weight
Point：Verapamil 0.05%, Tea Polyphenols 0.01%, allicin 0.03%, glucocorticoid medicine 0.005%, vitamin
B20.001%, taurine 0.01%.Described glucocorticoid medicine is dexamethasone.
The preparation method of described buccal tablet is：(1) weigh Verapamil 0.5g, Tea Polyphenols 0.1g, allicin 0.3g, fill in
The loose 0.05g of rice, vitamin B2 0.01g, taurine 0.1g, are mixed with 50g malt saccharin respectively, sieve, add 250g Icing Sugar,
Sieve, obtain mixed-powder；(2) menthol containing sheet weight 0.6% is dissolved in 175mL absolute ethyl alcohol, adds in mixed-powder,
Mix, dry；(3) with 65% syrup of 120mL or 1%HPMC solution 110mL as adhesive, softwood processed simultaneously crosses sieve series
Grain；(4) whole grain compressing tablet, prepared compound buccal tablet.
Embodiment 2
A kind of compound preparation treating chronic pharyngitis, described compound Western medicine preparation includes effective group of following parts by weight
Point：Verapamil 1.2%, Tea Polyphenols 1.0%, allicin 1.5%, glucocorticoid medicine 0.018%, vitamin
B20.005%, taurine 0.5%.Described glucocorticoid medicine is Triamcinolone acetonide.
The preparation method of described oral administration solution is：(1) Verapamil 12g, Tea Polyphenols 10g, allicin 15g, Qu An are weighed
How moral 0.18g, vitamin B2 0.05g, taurine 5g, standby；(2) by Verapamil 12g, vitamin B2 0.05g and Tea Polyphenols
10g 250mL distills water dissolves, adds 60g 400mL to distill water-soluble Tween 80, stirring and dissolving mixes；(3) distinguish again
Add the aqueous solution 80mL of aqueous solution 80mL, dissolving 15g allicin and 5g taurine of dissolving 0.18g Triamcinolone acetonide and be dissolved in
300mL temperature is the 10g menthol in 105 DEG C of hot water, uniformly obtains final product oral administration solution using ultrasonic mixing.
Embodiment 3
Described compound Western medicine preparation includes the active principle of following parts by weight：Verapamil 0.12%, Tea Polyphenols
0.15%th, allicin 0.55%, glucocorticoid medicine 0.015%, vitamin B2 0.003%, taurine 0.15%.Described
Glucocorticoid medicine is budesonide.
The preparation method of described buccal tablet is：(1) Verapamil 1.2g, Tea Polyphenols 1.5g, allicin 5.5g, cloth ground are weighed
How moral 0.15g, vitamin B2 0.03g, taurine 1.5g, is mixed with 50g malt saccharin respectively, sieves, add 300g Icing Sugar,
Sieve, obtain mixed-powder；(2) menthol containing sheet weight 0.7% is dissolved in 180mL absolute ethyl alcohol, adds in mixed-powder,
Mix, dry；(3) with 70% syrup of 130mL or 2%HPMC solution 115mL as adhesive, softwood processed simultaneously crosses sieve series
Grain；(4) whole grain compressing tablet, prepared compound buccal tablet.
Animal pharmacodynamic study
First, toxicity test：
Animal used as test：Small white mouse, provided by Hefei City's animal experimental center.
Mice lavage is administered acute toxicity test：
Test method：100 small white mouses after adaptability feeds 7 days in laboratory conditions, are randomly divided into 2 groups, that is, real
Test group and control group, every group 50.After fasting 12h (can't help water), experimental group gives the oral administration solution preparing as embodiment 2
Gavage, control group gives physiological saline gavage.Situations such as after observing gavage in seven days, the spirit of small white mouse, behavior, diet are intended to, note
Record mice dying T/A, cut open inspection death small white mouse, observe the pathological change of each organs and tissues.
Experimental result：None death of small white mouse in seven days, puts to death each internal organs of small white mouse anatomic observation and does not find toxic reaction,
Experimental group and the no any difference of control group small white mouse.
Wistar rat oral gavage is administered long term toxicity test：
Test method：
(1) choose wSPF level rat 100, body weight 200 ± 30g, be divided into two groups, i.e. control group, experimental group, every group 50
Only.
(2) experimental group gives the oral administration solution medicine gavage preparing as embodiment 2, and dosage is to be equivalent to adult's medication
5 times, control group gives physiological saline gavage, gavage three times on the one, successive administration 3 months, observes animal ordinary circumstance and body weight
Etc. index.After stopping three days, the index such as the spirit of observation wistar rat, behavior, diet desire, body weight.
Result of the test：
The indexs such as the spirit of wistar rat, behavior, diet desire, body weight have no significant change.Put to death rat, to its internal organ
Carry out under histotomy, Electronic Speculum, showing no any pathology and exception.
2nd, antitussive effect research
(1) foundation of cough animal model and screening
Draw with ammoniacal liquor to cough and set up the animal cough model qualified mouse of screening, cause mouse to cough with ultrasonic atomizer aerosol ammoniacal liquor
Cough.Record cough number of times with multi-channel Physiological Signal Acquiring System Rm6240.Concrete operations are：Kunming mouse is put into traverse
In wide-mouth bottle, bottleneck is stoppered with the rubber stopper beating holes, and the flexible pipe in one of hole connects ultrasonic atomizer, soft in another hole
Pipe connects physiograph.Step up to connect the clip of atomizer, record normal respiratory wave 10s, then open clip, beat simultaneously
Drive atomizer, spray 4mol/L ammoniacal liquor 30s, then clamps two clips rapidly, closes atomizer, records the respiratory wave of 3min,
Mouse cough number of times in record 3min.In 3min, cough number of times is the mouse successfully modeling for 15-30 time.
(2) animal packet and administration
22-28g is taken successfully to model mouse 40, male female dual-purpose.It is divided into 4 groups by cough number of times and sex stratified random, point
Other intraperitoneal injection of saline, the aqueous solution of buccal tablet of embodiment 1 preparation, the aqueous solution of buccal tablet of embodiment 3 preparation, reality
Apply the oral administration solution of example 2 preparation, after 20min, ammoniacal liquor draws to be coughed, cough number of times in record 3min.
(3) statistical procedures
Experimental data is represented with X ± S, and group difference is checked with t, the results are shown in Table 1.
| Project | Cough number of times |
| Embodiment 1 | 20±1.8 |
| Embodiment 2 | 16±2.2 |
| Embodiment 3 | 13±2.0 |
As can be seen from the above table, this compound Western medicine preparation can effectively reduce cough number of times, and antibechic effect is preferable.
3rd, anti-microbial property test
Weigh the compound Western medicine preparation that embodiment 1-3 is obtained, after sterilized process, be added to the culture containing certain bacterium amount
In liquid, then shaken cultivation 24h when 37 DEG C, after each test tube shakes up, take out the mixed liquor 100 μ L after culture respectively and be added to enzyme mark
On reaction plate, measure OD value at enzyme mark analyzer 570nm wavelength, calculate the bacteriostasis rate of bacterium, result see table.
As can be seen from the above table, the compound Western medicine preparation of the present invention has preferable anti-microbial property.
4th, antiinflammatory action
(1) detection of the foundation of rat inflammation model and index
40 Wistar rats are randomly divided into modeling group, natural recovering group, counterevidence group, 4 groups of blank control group, every group 10
Only.
Modeling group：The 1-3d upper and lower noon is respectively sprayed its pharyngeal 1 time with 15% ammoniacal liquor, is pressed with sprayer spray 3 every time, 5d breaks
Tail takes blood film.
Compound spray treatment group：With modeling group, 5-7d laryngeal spray feeds this west to rat to pharyngeal spray ammoniacal liquor
Medicine compound preparation (according to big and rat body surface coefficient conversion), the daily morning and evening is each once, and 7d docking takes blood film.
Blank control group：Spray equivalent distilled water.
Positive controls：The dexamethasone sodium phosphate of the dosage folk prescriptions such as spray, 5d docking takes blood film.
After each group animal takes blood film, take off pharyngeal mucosa immediately after femoral artery sacrificed by exsanguination animal and its undertissue cuts
Piece is observed.Docking before each group animal is put to death takes blood film to measure routine blood test.
Test result indicate that：By pharyngeal pathological examination, model group and blank control group rat swallow the viscous of tissue
Film epithelium outer layer keratinisation, partial exfoliation, the obvious hyperplasia of mucous epithelium layer, submucosa is thin, and part muccus gland epithelial layer is obvious
Hyperplasia, the no obvious line of demarcation with tunica propria, the thin vessels expansion in tunica propria, congested, oedema, between intrinsic diaphragm area and muccus gland
There is substantial amounts of inflammatory cell infiltration.Basically identical with the pathological manifestations of Clinical Acute pharyngitis, model success.
The compound preparation of the treatment chronic pharyngitis of the present invention have have no toxic side effect, be not in concurrent after long-term taking
Disease, the advantage that treatment cycle is short, therapeutic effect is good；And medicine is in good taste, production method is simple, low production cost；By reality
The compound preparation demonstrating this treatment chronic pharyngitis has good cough-relieving, anti-inflammatory, bacteriostasis, has preferable promotion price
Value.
Above the better embodiment of this patent is explained in detail, but this patent is not limited to above-mentioned embodiment party
Formula, in the ken that one skilled in the relevant art possesses, can also be on the premise of without departing from this patent objective
Make a variety of changes.
Claims (8)
1. a kind of compound preparation treating chronic pharyngitis is it is characterised in that described compound Western medicine preparation includes following parts by weight
Active principle：Verapamil 0.05-1.2%, Tea Polyphenols 0.01-1.0%, allicin 0.03-1.5%, glucocorticoids
Medicine 0.005-0.018%, vitamin B2 0.001-0.005%, taurine 0.01-0.5%.
2. the compound preparation for the treatment of chronic pharyngitis according to claim 1 is it is characterised in that described glucocorticoids medicine
Thing is one of dexamethasone, Triamcinolone acetonide, budesonide, hydrocortisone.
3. the compound preparation for the treatment of chronic pharyngitis according to claim 1 is it is characterised in that described compound Western medicine preparation bag
Include the active principle of following parts by weight：Verapamil 0.06-0.35%, Tea Polyphenols 0.05-0.65%, allicin 0.05-
0.65%th, glucocorticoid medicine 0.012-0.017%, vitamin B2 0.002-0.004%, taurine 0.12-
0.25%.
4. the compound preparation for the treatment of chronic pharyngitis according to claim 1 is it is characterised in that described compound Western medicine preparation bag
Include the active principle of following parts by weight：Verapamil 0.12%, Tea Polyphenols 0.15%, allicin 0.55%, glucocorticoid
Class medicine 0.015%, vitamin B2 0.003%, taurine 0.15%.
5. the compound preparation according to the arbitrary described treatment chronic pharyngitis of claim 1-4 is it is characterised in that described Western medicine compound
Preparation is tablet, granule, oral administration solution, spray or nasal drop.
6. the compound preparation for the treatment of chronic pharyngitis according to claim 5 is it is characterised in that described compound Western medicine preparation is
Buccal tablet or oral administration solution.
7. a kind of preparation method of the compound preparation for the treatment of chronic pharyngitis as claimed in claim 6 is it is characterised in that described mouth
The preparation method of lozenge is：(1) Verapamil 0.5-12g, Tea Polyphenols 0.1-10g, allicin 0.3-15g, sugared cortical hormone are weighed
Plain class medicine 0.05-0.18g, vitamin B2 0.01-0.05g, taurine 0.1-5g, are mixed with 50g malt saccharin, mistake respectively
Sieve, adds 250-400g Icing Sugar, sieves, obtain mixed-powder；(2) menthol containing sheet weight 0.6-1% is dissolved in 175-
200mL absolute ethyl alcohol, adds in mixed-powder, mixes, and dries；(3) with the 65-75% syrup of 120-150mL or 1-3%
HPMC solution 110-115mL is adhesive, softwood processed granulation of sieving；(4) whole grain compressing tablet, prepared compound buccal tablet.
8. a kind of preparation method of the compound preparation for the treatment of chronic pharyngitis as claimed in claim 6 is it is characterised in that described mouth
The preparation method taking solution is：(1) Verapamil 0.5-12g, Tea Polyphenols 0.1-10g, allicin 0.3-15g, sugared cortex are weighed
Hormone medicine 0.05-0.18g, vitamin B2 0.01-0.05g, taurine 0.1-5g, standby；(2) by Verapamil 0.5-
12g, vitamin B2 0.01-0.05g and Tea Polyphenols 0.1-10g 150-250mL distill water dissolves, add 55-60g 350-
400mL distills water-soluble Tween 80, and stirring and dissolving mixes；(3) it is separately added into dissolving 0.05-0.18g glucocorticoids again
The aqueous solution 55-80mL of medicine, dissolving 0.3-15g allicin and the aqueous solution 55-80mL of 0.1-5g taurine and be dissolved in 250-
300mL temperature is the 8-10g menthol in 55-105 DEG C of hot water, uniformly obtains final product oral administration solution using ultrasonic mixing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611024270.1A CN106421137A (en) | 2016-11-17 | 2016-11-17 | Compound preparation for treating chronic pharyngitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611024270.1A CN106421137A (en) | 2016-11-17 | 2016-11-17 | Compound preparation for treating chronic pharyngitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106421137A true CN106421137A (en) | 2017-02-22 |
Family
ID=58220544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611024270.1A Pending CN106421137A (en) | 2016-11-17 | 2016-11-17 | Compound preparation for treating chronic pharyngitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106421137A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106860754A (en) * | 2017-02-23 | 2017-06-20 | 谢松甫 | A kind of pharmaceutical composition for treating chronic pharyngitis |
| CN108686198A (en) * | 2018-06-20 | 2018-10-23 | 广西信业生物技术有限公司 | A kind of spraying dressing and preparation method thereof for treating chronic pharyngitis |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1313084A (en) * | 2000-03-09 | 2001-09-19 | 陈建操 | Application of tea polyphenol in medicine to treat diseases in respiratory system |
| CN1480134A (en) * | 2003-07-18 | 2004-03-10 | 曾雄飞 | Combination of iodine amino acid as well as its preparation method and application |
| CN101466716A (en) * | 2006-04-07 | 2009-06-24 | 德维洛根股份公司 | Thienopyrimidines having MNKL/MNK2 inhibiting activity for pharmaceutical compositions |
| CN101757629A (en) * | 2010-02-05 | 2010-06-30 | 张福成 | Medicine composition for treating acute and chronic aryngitis and preparation method thereof |
| CN102949516A (en) * | 2012-11-14 | 2013-03-06 | 西安福安创意咨询有限责任公司 | Health-care product lozenge for pharyngitis and preparation method thereof |
-
2016
- 2016-11-17 CN CN201611024270.1A patent/CN106421137A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1313084A (en) * | 2000-03-09 | 2001-09-19 | 陈建操 | Application of tea polyphenol in medicine to treat diseases in respiratory system |
| CN1480134A (en) * | 2003-07-18 | 2004-03-10 | 曾雄飞 | Combination of iodine amino acid as well as its preparation method and application |
| CN101466716A (en) * | 2006-04-07 | 2009-06-24 | 德维洛根股份公司 | Thienopyrimidines having MNKL/MNK2 inhibiting activity for pharmaceutical compositions |
| CN101757629A (en) * | 2010-02-05 | 2010-06-30 | 张福成 | Medicine composition for treating acute and chronic aryngitis and preparation method thereof |
| CN102949516A (en) * | 2012-11-14 | 2013-03-06 | 西安福安创意咨询有限责任公司 | Health-care product lozenge for pharyngitis and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 杨璞: "《健康谣言粉碎机》", 31 May 2014, 中国医药科技出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106860754A (en) * | 2017-02-23 | 2017-06-20 | 谢松甫 | A kind of pharmaceutical composition for treating chronic pharyngitis |
| CN108686198A (en) * | 2018-06-20 | 2018-10-23 | 广西信业生物技术有限公司 | A kind of spraying dressing and preparation method thereof for treating chronic pharyngitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11583519B2 (en) | Nasal compositions and method of use thereof | |
| CN101953821A (en) | Medicinal composition taking levalbuterol and ambroxol as main active ingredients | |
| CN102319294B (en) | Double-vanilla preparation and preparation method thereof | |
| CN101637561A (en) | Fritillary-loquat medicinal composition and preparation method thereof | |
| CN106421137A (en) | Compound preparation for treating chronic pharyngitis | |
| CN102362966A (en) | Unibract fritillary bulb and loquat leaf medicinal composition and preparation method thereof | |
| CN100386071C (en) | Medicine for treating cough and chronic bronchitis | |
| CN106389445A (en) | Western medicine compound preparation for treating chronic pharyngitis | |
| CN104225196B (en) | Traditional Chinese medicine effervescent tablet for treating respiratory diseases and preparation method of traditional Chinese medicine effervescent tablet | |
| CN102106999B (en) | A kind of compound Chinese medicinal preparation for the treatment of dysphagia after apoplexy and preparation method thereof | |
| CN106727607A (en) | A kind of compound Western medicine preparation for treating sphagitis | |
| CN104840737B (en) | Chinese medicine composition with qi invigorating and lung moistening effect and its preparation method and application | |
| CN111358875A (en) | Traditional Chinese medicine composition for treating gastroesophageal reflux cough and preparation method thereof | |
| CN105997949B (en) | A kind of bulleyaconitine A orodispersible film preparation and its preparation process | |
| CN1686211A (en) | Medicine for treating acute and chronic pharyogolaryngitis, recurring oral cavity sore and its preparation method | |
| CN102188574A (en) | Chinese medicine composition for treating influenza A virus bronchitis and preparation method thereof | |
| CN1270762C (en) | Cough stopping and asthma relieving medicine and its preparation | |
| CN106511394B (en) | Application of aspongopus fatty oil extract | |
| CN1239178C (en) | Method for preparing qingkailing granules | |
| CN104586979A (en) | Cough-relieving oral liquid and preparation method thereof | |
| CN104042811A (en) | Externally applied compound medicament for treating catabasis of bronchial asthma, preparation method and application thereof | |
| CN110151925A (en) | A kind of composition and its preparation method and application with function of moistening and cleaning throat | |
| CN108785559A (en) | A kind of drug and preparation method thereof for treating respiratory tract infection | |
| CN102188498B (en) | Traditional Chinese medicine composition for treating pediatric high fever and preparation method thereof | |
| CN108186947A (en) | A kind of Chinese medicine composition and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170222 |
|
| RJ01 | Rejection of invention patent application after publication |